Molecular and Cellular Biology of Cancer In the News
City of Hope scientists highlighted research successes and presented recent findings at the 2019 American Diabetes Association’s Scientific Sessions.
John Rossi, Ph.D., the Lidow Family Research Chair and professor of the Department of Molecular and Cellular Biology, is the recipient of the 2019 Outstanding Achievement Award presented by the American Society of Gene and Cell Therapy.
A City of Hope scientist and his colleagues have developed a user-friendly approach to creating “theranostics” — therapy combined with diagnostics — that target specific tumors and diseases.
A City of Hope scientist and his colleagues have developed a user-friendly approach to creating “theranostics” – therapy combined with diagnostics – that target specific tumors and diseases.
City of Hope has long been renowned for its expertise in treating cancer and diabetes. But specialists here also are tackling lesser-known but equally devastating diseases that may or may not have an oncologic component.
Debbie Thurmond, Ph.D., delivers and accepts the John K. and Mary E. Davidson Lectureship and Award for Outstanding Diabetes Research
In January 1979, the National Academy of Sciences published a paper about an innovative discovery at City of Hope that would forever change how diabetes is treated. Arthur Riggs, Ph.D., and Keiichi Itakura, Ph.D., revolutionized diabetes treatment when they made a novel gene, one that coded for human insulin.
Sampath Rangasamy, Ph.D., a researcher at City of Hope affiliate TGen, has spent his whole life researching type 1 diabetes, a personal battle since he himself suffers from the disease.
Recently a team of researchers led by City of Hope scientists identified a new potential target to keep the immune system stable and islet beta cells healthy, in an effort to keep type 1 diabetes at bay.
As a Ph.D. candidate at City of Hope, Li Li's work with Alexander disease may also shed new light on similar neurodegenerative conditions such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis.
A City of Hope researcher has developed a stem cell model to assess possible treatments for a rare nervous system disorder that is in the same disease group as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The finding takes scientists one step closer to finding a way to slow or treat Alzheimer’s disease and other neurodegenerative disorders.
Many people struggle with both diabetes and cancer at the same time — none of this is random or coincidental. Rather, it's clear that, from biology to risk factors to treatment options, cancer and diabetes are intimately related in many ways.
In an effort to improve options for those with liver cancer, a group of researchers have identified a way of potentially treating a broad range of liver diseases and perhaps even other types of cancer.
In an effort to understand cancer on a cellular level, a team of City of Hope researchers have been examining DNA deletions and their role in the disease.
Every so often, as City of Hope’s Arthur Riggs, Ph.D., knows well, “forgotten” work can provide groundbreaking insight for new research years later.
City of Hope researchers have found a link between a type of ancient RNA and a tumor suppressing gene.
Students spent 10 weeks this summer at the Eugene and Ruth Roberts Summer Student Academy, designed to give hardworking students the opportunity to learn about science by working in a laboratory setting.
A collaboration with The Jackson Laboratory expands access to leading-edge research capabilities to find new treatments for life-threatening diseases.
City of Hope’s rich history is filled with stories of celebrated researchers who helped shape the course of modern medicine. Yoko Fujita-Yamaguchi, Ph.D., professor emeritus in the Diabetes & Metabolism Research Institute at City of Hope, has written a book in Japanese that delves into the contributions of Japanese-American scientists at City of Hope.
An international team of researchers led by City of Hope’s Defu Zeng believe they may have found a way to prevent graft-versus host disease following stem cell transplants without sacrificing the transplants’ ability to fight leukemia and lymphoma.